Cartesian Therapeutics
RNAC
61 hedge funds and large institutions have $85.6M invested in Cartesian Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 27 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
47% more capital invested
Capital invested by funds: $58.3M → $85.6M (+$27.3M)
16.7% more ownership
Funds ownership: 1.13% → 17.82% (+17%)
12% less funds holding
Funds holding: 69 → 61 (-8)
26% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.2M |
| 2 |
JP Morgan Chase
New York
|
+$6.18M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.78M |
| 4 |
BlackRock
New York
|
+$3.96M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$23M |
| 2 |
Millennium Management
New York
|
-$647K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$199K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$159K |
| 5 |
Jane Street
New York
|
-$124K |
RNAC Hedge Fund Activity: Q2 2024 in Review
61 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2024, worth a combined $85.6M — up 47% from $58.3M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of RNAC and 20 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 25 added.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $6.2M. The largest seller was Goldman Sachs, exiting entirely with an estimated $23M sold.
- 61 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2024, down from 69 in Q1 2024.
- Funds reported $85.6M of Cartesian Therapeutics stock for Q2 2024, up 47% quarter-over-quarter.
- 20 funds opened new Cartesian Therapeutics positions in Q2 2024 and 27 closed out, a net change of -7 holders.
- The largest Cartesian Therapeutics buyer in Q2 2024 was MPM BioImpact, an estimated $6.2M added.
- The largest Cartesian Therapeutics seller in Q2 2024 was Goldman Sachs, an estimated $23M sold.
Based on aggregated 13F filings for Q2 2024.